Paul Voss joins Rezolute with over 25 years of biopharmaceutical commercialization experience. He brings a proven product launch, strategic market access and patient / provider services track record, with emphasis on ultra-rare and orphan disease.

Prior to joining Rezolute, Paul held executive leadership roles at a number of emerging companies, including Reneo Pharmaceuticals, Marinus Pharmaceuticals, and Ionis and Akcea Therapeutics, with focus on product value, pricing and reimbursement for payer, HTA, and organized system customer engagement. His success in industry results from focus on patient experience and outcomes while delivering on product commercial and corporate value.

Paul received his B.S. in exercise physiology from Oregon State University.